Deborah J. Wexler, MD, MSc

Massachusetts General Hospital, United States

Disclosure information not submitted.

Presentation(s):

• Comparing Healthcare Utilization and Cost in Empagliflozin vs GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease

  Tuesday, August 27, 2024
  8:30 AM – 8:45 AM CEST

• The risk of cardiovascular (CV) events after initiation of SGLT2i, GLP-1RA, DPP4i, or SUs in patients with T2D and low-to-moderate CV risk

  Wednesday, August 28, 2024
  9:00 AM – 9:15 AM CEST

• Head-to-head Comparison of Dapagliflozin vs Empagliflozin: Cardiovascular and Safety Events

  Wednesday, August 28, 2024
  9:45 AM – 10:00 AM CEST